Previous 10 | Next 10 |
Immunocore to present at the 41 st Annual J . P . Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company ...
Summary Clinical trial momentum within the Melanoma diagnostics and treatment paradigm is gaining steam. Immunocore Holdings plc presents with unique exposure for investors to position at the treatment end of the spectrum. Recent advancements in its investigational compounds are wel...
Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye. (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 15 December 20...
Immunocore p resents ovarian cancer expansion d ata for ImmTAC ® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers , with vast majority of patients having zero or very low MAGE-A4 expression ...
Immunocore and Gadeta A nnounce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for S olid Tumors Gamma delta TCRs off er potential to address large number of patients without HLA restrict ion...
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the deve...
Immunocore presents new biomarker analysis for KIMMTRAK ( tebentafusp -tebn ) in metastatic uveal melanoma at the SITC 2022 Annual Meeting E xpression of gp100 protein , the target of KIMMTRAK, is unchange...
Medison Pharma said South and Central Americas and the Caribbean markets (Latin America) were added to its multi-territorial agreement with Immunocore ( NASDAQ: IMCR ). Immunocore's drug Kimmtrak is approved to treat a type of eye cancer called uveal melanoma in the U....
Immunocore press release ( NASDAQ: IMCR ): Q3 GAAP EPS of $0.13 beats by $0.44 . Revenue of $45.87M (+474.8% Y/Y) beats by $11.15M . For further details see: Immunocore GAAP EPS of $0.13 beats by $0.44, revenue of $45.87M beats by $11.15M
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity data for IMC-F106C, the first off-the-shelf TCR therapy targe...
News, Short Squeeze, Breakout and More Instantly...
Immunocore Holdings plc Company Name:
IMCR Stock Symbol:
NASDAQ Market:
Immunocore Holdings plc Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
A look at the top 10 most actives in the United States NLS Pharmaceutics Ltd. (NLSP) rose 156.2% to $0.38 on volume of 125,047,059 shares Reliance Global Group Inc. (RELI) rose 210.8% to $0.69 on volume of 110,427,102 shares Mustang Bio Inc. (MBIO) rose 53.3% to $1.15 on volume of 87,727,...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma The Phase 3 PRISM-MEL-301 trial will study the efficacy and safety of brenetafusp (IMC-F10...